informational purposes only.
Metformin Hydrochloride Tablet
Xmet 250 tablet
Xmet 250 tablet is prescribed for the treatment of type 2 diabetes mellitus.
Xmet 250 tablet Composition :-
Metformin Hydrochloride ................ 250mg
Xmet 250 Tablet Uses :-
Xmet 250 tablet is used in the treatment of type 2 diabetes mellitus. Xmet 250 tablet helps to control blood sugar level and prevents serious complications of diabetes.
By lowering or controlling blood sugar levels in this way, you can reduce your risk of serious complications of diabetes such as kidney damage, nerve problems, eye damage and loss of organs.
When Xmet 250 tablet is used along with a healthy diet and exercise, it helps a lot in controlling blood sugar.
Apart from this, Xmet 250 tablet is used to treat polycystic ovary syndrome (PCOS), a menstrual disorder in women.
Xmet 250 Tablet Dosage :-
Xmet 250 tablet is a prescription medicine. Take Xmet 250 tablet as directed by your doctor. Use Xmet 250 tablet exactly as directed by the doctor. Do not take a higher or lower dose than directed by your doctor.
Xmet 250 tablet should be taken during or after a meal. Never self-medicate or change the dosage without a doctor's advice. Do not take 2 or more doses at the same time.
Always try to take Xmet 250 tablet on regular schedule. Always take the tablet even if you feel well or your blood sugar level is under control. Do not stop taking without your doctor's advice. Otherwise, your blood sugar level may rise again. Do not stop taking Metformin hydrochloride tablet without asking your doctor. Because the treatment of diabetes is lifelong.
How Does Xmet 250 tablet Work :-
Xmet 250 tablet contains : Metformin Hydrochloride.
Metformin Hydrochloride :
Metformin hydrochloride is an antidiabetic medicine belonging to a class of drugs called biguanides.
Metformin delays the absorption of glucose from the intestines, by reducing the production of glucose in the liver. And thus metformin works by increasing the sensitivity of the body to insulin.
Thus Xmet 250 tablet works by controlling the level of sugar in the blood.
Xmet 250 Tablet Sideeffects :-
Low blood sugar (hypoglycemia),
Nausea,
Vomiting,
Change in taste,
Diarrhea,
Stomach ache,
Stomach enlargement,
Loss of appetite and many other side effects can occur.
Xmet 250 Tablet Price:-
MRP ₹ : 22.50 ( 15 tabs )
MRP ₹ : 22.50 ( 15 tabs )
Packing Information :-
Xmet 250 Tablet Marketed By :-
Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Ltd
Xmet 250 Tablet Self life :-
Please see the expiry date/manufacture date printed on Xmet 250 tablet pack.
Please see the expiry date/manufacture date printed on Xmet 250 tablet pack.
Safety Advice :-
Pregnancy : Safe
Xmet 250 tablet is safe to use during pregnancy. Animal studies have shown no or no adverse effects on the developing baby.
Breastfeeding : Safe
Xmet 250 tablet is safe to use during breastfeeding. Limited human data suggests that Xmet 250 does not represent any risk to the baby.
Driving : Caution
Your ability to drive may be affected if your blood sugar is too high or low during treatment with Xmet 250 tablet. Do not drive if you have these symptoms.
Kidney : Caution
Xmet 250 tablet should be used with caution in patients with kidney disease. Dose adjustment of Xmet 250 tablet may be needed. Consult your doctor for this. Use of Xmet 250 tablet is generally not advised in patients with severe kidney disease. Regular monitoring of kidney function tests is advised while you are taking Xmet 250 tablet.
Liver : Caution
Xmet 250 tablet should be used with caution in patients with liver disease. Dose adjustment of Xmet 250 tablet may be needed. Consult your doctor for this. Low dose of Xmet 250 tablet is generally started in patients with mild liver disease and use of Xmet 250 tablet is not recommended in patients with severe liver disease.
Alcohol : Unsafe
It is unsafe to consume alcohol while taking Xmet 250 tablet. Therefore, do not consume alcohol after taking Xmet 250 tablet.
Classification :-
Therapeutic Class - Antidiabetic drugs, biguanides,
Information on this page was last updated on 24 September 2021